rhNGF recombinant human nerve growth factor regulatory update

Dompe said the European Commission granted Orphan Drug designation for its rhNGF to treat retinitis pigmentosa. The product is in the Phase I/II REPARO trial to treat neurotrophic keratitis. Dompe gai...